TESAMORELIN ACETATE - Food and Drug Administration

Set ID: 6bd59cd9-c847-4812-bf4a-c404905392f8
Type: Indexing - product concept
Effective date: 2026-01-08
Version: 1
Source: DailyMed source

Mapped DailyMed Labels#

Label, Relation, Manufacturer table
Label	Relation	Manufacturer	Effective
These highlights do not include all the information needed to use EGRIFTA SV safely and effectively. See full prescribing information for EGRIFTA SV. EGRIFTA SV ® (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Product name	Theratechnologies Inc.	2026-07-29
These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Product name	Theratechnologies Inc.	2026-07-29
These highlights do not include all the information needed to use EGRIFTA SV safely and effectively. See full prescribing information for EGRIFTA SV. EGRIFTA SV ® (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Product name	Theratechnologies Inc.	2025-12-23
These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Product name	Theratechnologies Inc.	2025-03-31

NDC, DailyMed label, Manufacturer table
NDC	DailyMed label	Manufacturer
0409-3977	These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.
62064-241	These highlights do not include all the information needed to use EGRIFTA SV safely and effectively. See full prescribing information for EGRIFTA SV. EGRIFTA SV ® (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.
62064-241-30	These highlights do not include all the information needed to use EGRIFTA SV safely and effectively. See full prescribing information for EGRIFTA SV. EGRIFTA SV ® (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.
62064-371	These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.
62064-371-01	These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.
62064-381	These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.
62064-381-04	These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	Theratechnologies Inc.